Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now
Key Stock Data
The current last sale of $66.47 is 28.77% Higher than the 52 week low.
|Intraday||Last 52 Weeks|
|High:||$ 69.945||$ 99.8242|
|Low:||$ 66.08||$ 51.62|
ETFs with AGIO as a Top 10 Holding*
|Weighting||ETF Name (Symbol)||100-Day Price Change (%)|
|293%||ALPS Medical Breakthroughs ETF (SBIO)||-3.24 (-8.84%)|
|3.6%||First Trust Amex Biotech Index Fund (FBT)||-1.22 (-0.89%)|
|0%||AGFiQ U.S. Market Neutral Size Fund (SIZ)||-0.28 (-1.40%)|
|*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green highlights the top performing ETF by % change in the past 100 days.|
Company Description (as filed with the SEC)
Item 1. Business We are a biopharmaceutical company committed to the fundamental transformation of patients' lives through scientific leadership in the field of cellular metabolism, with the goal of making transformative, first- or best-in-class medicines. Our therapeutic areas of focus are cancer and rare genetic diseases, or RGDs, which are diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. Most RGDs are often associated with severe or life-threatening features. The incidence of a single RGD can vary widely but is generally very infrequent, usually equal to or less than one per 100,000 births. In both areas of cancer and RGDs, we are seeking to unlock the biology of cellular metabolism as a platform to create transformative therapies. Our first commercial cancer product is IDHIFA®. ... More ...
Nasdaq Official Price
Nov. 19, 2018
Nov. 19, 2018